Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
| العنوان: | Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival |
|---|---|
| المؤلفون: | Htut, Myo, D'Souza, Anita, Krishnan, Amrita, Bruno, Benedetto, Zhang, Mei-Jie, Fei, Mingwei, Diaz, Miguel Angel, Copelan, Edward, Ganguly, Siddhartha, Hamadani, Mehdi, Kharfan-Dabaja, Mohamed, Lazarus, Hillard, Lee, Cindy, Meehan, Kenneth, Nishihori, Taiga, Saad, Ayman, Seo, Sachiko, Ramanathan, Muthalagu, Usmani, Saad Z, Gasparetto, Christina, Mark, Tomer M, Nieto, Yago, Hari, Parameswaran |
| المصدر: | Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Adult, Male, Survival, Hematopoietic Stem Cell Transplantation, Myeloma, Middle Aged, Allografts, Disease-Free Survival, Survival Rate, Sex Factors, Recurrence, Risk Factors, Allogeneic transplantation, Humans, Female, Relapse, Autografts, Multiple Myeloma, Aged |
| الوصف: | We compared postrelapse overall survival (OS) after autologous/allogeneic (auto/allo) versus tandem autologous (auto/auto) hematopoietic cell transplantation (HCT) in patients with multiple myeloma (MM). Postrelapse survival of patients receiving an auto/auto or auto/allo HCT for MM and prospectively reported to the Center for International Blood and Marrow Transplant Research between 2000 and 2010 were analyzed. Relapse occurred in 404 patients (72.4%) in the auto/auto group and in 178 patients (67.4%) in the auto/allo group after a median follow-up of 8.5 years. Relapse occurred before 6 months after a second HCT in 46% of the auto/allo patients, compared with 26% of the auto/auto patients. The 6-year postrelapse survival was better in the auto/allo group compared with the auto/auto group (44% versus 35%; P = .05). Mortality due to MM was 69% (n = 101) in the auto/allo group and 83% (n = 229) deaths in auto/auto group. In multivariate analysis, both cohorts had a similar risk of death in the first year after relapse (hazard ratio [HR], .72; P = .12); however, for time points beyond 12 months after relapse, overall survival was superior in the auto/allo cohort (HR for death in auto/auto =1.55; P = .005). Other factors associated with superior survival were enrollment in a clinical trial for HCT, male sex, and use of novel agents at induction before HCT. Our findings shown superior survival afterrelapse in auto/allo HCT recipients compared with auto/auto HCT recipients. This likely reflects a better response to salvage therapy, such as immunomodulatory drugs, potentiated by a donor-derived immunologic milieu. Further augmentation of the post-allo-HCT immune system with new immunotherapies, such as monoclonal antibodies, checkpoint inhibitors, and others, merit investigation. |
| وصف الملف: | application/pdf |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::3a9c27411c6b0ae966f908b1ef5d8619Test https://hdl.handle.net/20.500.12530/29949Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.RECOLECTA.....3a9c27411c6b0ae966f908b1ef5d8619 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |